166941-67-9

Basic information

• Product Name: L-Proline, 5-methyl-, ethyl ester, trans- (9CI)
• Synonyms: L-Proline, 5-methyl-, ethyl ester, trans- (9CI)
• CAS NO: 166941-67-9
• Molecular Formula: C8H15NO2
• Molecular Weight: 157.2102
• Product Categories: PYRROLE;CARBOXYLICESTER
• Mol File: 166941-67-9.mol
• Article Data: 18

Chemical Properties

• Boiling Point: 203.7±33.0 °C(Predicted)
• Appearance: /
• Density: 0.989±0.06 g/cm3(Predicted)
• PKA: 8.66±0.10(Predicted)
• CAS DataBase Reference: L-Proline, 5-methyl-, ethyl ester, trans- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: L-Proline, 5-methyl-, ethyl ester, trans- (9CI)(166941-67-9)
• EPA Substance Registry System: L-Proline, 5-methyl-, ethyl ester, trans- (9CI)(166941-67-9)

Safety Data

• Hazardous Substances Data: 166941-67-9(Hazardous Substances Data)

Upstream product

• 194594-24-6 (2S)-1-t-butyl 2-ethyl 5-methoxypyrrolidine-1,2-dicarboxylate 
• 194594-23-5 5-hydroxy-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester 2-ethyl ester 
• 7149-65-7 ethyl (S)-pyroglutamate 
• 144978-35-8 (S)-ethyl N-tert-butoxycarbonylpyroglutamate 
• 913251-58-8 (S)-2-(tert-butoxycarbonylamino)-5-oxohexanoic acid ethyl ester 
• 896733-29-2 (S)-5-methyl-3,4-dihydro-2H-pyrrole-2-carboxylic acid ethyl ester 
• 66183-71-9 ethyl 2-oxopyrrolidine-5-carboxylate 
• 149-87-1 Pyroglutamic acid 
• 100911-28-2 5-methyl-3,4-dihydro-2H-pyrrole-2-carboxylic acid ethyl ester 
• 251924-83-1 1-tert-butyl 2-ethyl 5-oxopyrrolidine-1,2-dicarboxylate 
• 73472-94-3 ethyl 3-bromo-2-(hydroxyimino)propanoate 

Downstream Products

• 1621508-43-7 ethyl 2-((benzyloxy)methyl)-5-methylpyrrolidine-2-carboxylate trifluoroacetate 
• 1621508-45-9 ethyl 1-benzyl-2-(hydroxymethyl)-5-methylpyrrolidine-2-carboxylate 
• 1621508-46-0 1-benzyl-2-(hydroxymethyl)-5-methylpyrrolidine-2-carboxylic acid 
• 1621508-02-8 cyclohexyl 2-(2-hydroxy-1-(pyrimidin-2-yl)propyl)-6-methyl-1-oxo-2,5-diazaspiro[3.4]octane-5-carboxylate 
• 1621508-52-8 1-benzyl-N-((1S,2R)-2-((tert-butoxydimethylsilyl)oxy)-1-(1,3,4-oxadiazol-2-yl)propyl)-2-(hydroxymethyl)-5-methylpyrrolidine-2-carboxamide 
• 1621508-53-9 5-benzyl-2-((1S,2R)-2-((tert-butoxydimethylsilyl)oxy)-1-(1,3,4-oxadiazol-2-yl)propyl)-6-methyl-2,5-diazaspiro[3.4]octan-1-one 
• 1621508-03-9 5-benzyl-2-((1S,2R)-2-hydroxy-1-(1,3,4-oxadiazol-2-yl)propyl)-6-methyl-2,5-diazaspiro[3.4]octan-1-one 
• 1621508-58-4 ethyl 1-benzyl-2-(1-hydroxyethyl)-5-methylpyrrolidine-2-carboxylate 
• 1621508-59-5 1-benzyl-2-(1-hydroxyethyl)-5-methylpyrrolidine-2-carboxylic acid 
• 1621527-25-0 1-benzyl-N-((1S,2R)-2-((tert-butyldimethylsilyl)oxy)-1-(1,3,4-oxadiazol-2-yl)propyl)-2-(1-hydroxyethyl)-5-methylpyrrolidine-2-carboxamide 
• 1621527-26-1 C₂₆H₄₀N₄O₃Si 
• 1621527-23-8 5-benzyl-2-((1S,2R)-2-hydroxy-1-(1,3,4-oxadiazol-2-yl)propyl)-3,6-dimethyl-2,5-diazaspiro[3.4]octan-1-one 
• 1621435-42-4 1-tert-butyl 2-ethyl 2-((benzyloxy)methyl)-5-methylpyrrolidine-1,2-dicarboxylate 
• 1621435-43-5 2-((benzyloxy)methyl)-1-(tert-butoxycarbonyl)-5-methylpyrrolidine-2-carboxylic acid 

Relevant articles and documents

Preparation method of chiral 5-substituted proline compound

The invention discloses a preparation method of a chiral 5-substituted proline compound. The preparation method comprises the following steps of: S1, Grignard reaction; S2, reduction reaction; S3, acylation reaction; and S4, hydrolysis reaction. The preparation method of the chiral 5-substituted proline compound is simple in synthetic route, simple and easy to implement, low in cost and mild in reaction; and chirality is formed by superior conformation generated by reduction reaction, so that large-scale production is easy, raw materials are easy to obtain, and the yield is high.

Deuterated antiviral active compounds for hepatitis C viruses

The invention relates to antiviral compounds for hepatitis C viruses (HCVs) and nontoxic pharmacologically-acceptable salts thereof, wherein the compounds are represented by a formula I shown in the description and have good bioavailability, and the compounds have potent inhibiting effects on the all-genotypic HCVs. In the structural formula I, R1, R2, R3 and R4 are independently selected from methyl (-CH3) or deuterated methyl (-CD3); X1, X2, X3, X4 and X5 are separately hydrogen (H) or deuterium (D); and one of the R1, the R2, the R3 and the R4 must be deuterated methyl (-CD3) or one of theX1, the X2, the X3, the X4, and the X5 must be deuterium (D).

BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF

Provided herein is a bridged bring compound of formula (I) or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating treat hepatitis C virus (HCV) infection or hepatitis C disease. Furthermore provided herein are pharmaceutical compositions containing the compounds and the method of using the compounds or pharmaceutical compositions thereof in the treatment of HCV infection or hepatitis C.